KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock Position Cut by EntryPoint Capital LLC

EntryPoint Capital LLC trimmed its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 52.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,509 shares of the specialty pharmaceutical company’s stock after selling 12,813 shares during the quarter. EntryPoint Capital LLC’s holdings in KalVista Pharmaceuticals were worth $97,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in KalVista Pharmaceuticals by 4.9% in the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock worth $19,102,000 after purchasing an additional 104,716 shares during the period. Intech Investment Management LLC raised its stake in shares of KalVista Pharmaceuticals by 58.5% in the 4th quarter. Intech Investment Management LLC now owns 17,204 shares of the specialty pharmaceutical company’s stock worth $146,000 after buying an additional 6,349 shares in the last quarter. AlphaQuest LLC lifted its holdings in shares of KalVista Pharmaceuticals by 17.1% in the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company’s stock valued at $150,000 after buying an additional 2,588 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after buying an additional 2,043 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Jones Trading reiterated a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Bank of America started coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $24.83.

Insiders Place Their Bets

In related news, insider Paul K. Audhya sold 3,125 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the sale, the insider now directly owns 100,334 shares in the company, valued at approximately $985,279.88. This trade represents a 3.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 6,669 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $11.97, for a total transaction of $79,827.93. Following the completion of the transaction, the chief executive officer now owns 287,811 shares in the company, valued at approximately $3,445,097.67. This represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 236,055 shares of company stock worth $2,162,146 and sold 17,292 shares worth $184,625. Corporate insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Stock Down 3.3 %

Shares of KalVista Pharmaceuticals stock opened at $11.93 on Monday. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50. The stock has a market cap of $593.11 million, a PE ratio of -3.28 and a beta of 0.76. The business has a fifty day simple moving average of $10.56 and a 200-day simple moving average of $10.25.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).